SCHEMBL2376773

SCHEMBL2376773

O=C(c1ccc(Br)c(Cl)c1)N1CCOCC1

nearest known ligand 0.75

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.75
HPGD P15428 4/20 0.71
PHGDH O43175 2/20 0.62
KMT2A Q03164 3/20 0.60
GLA P06280 1/20 0.60
AKR1C3 P42330 1/20 0.56
HSP90AA1 P07900 1/20 0.55
HSP90AB1 P08238 1/20 0.55
POLB P06746 3/20 0.54
TDP1 Q9NUW8 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
DNMT1 P26358 1/20 0.54
PTPN7 P35236 1/20 0.54
HTT P42858 1/20 0.54
KDM4E B2RXH2 1/20 0.54
NSD2 O96028 1/20 0.54
NR4A1 P22736 1/20 0.54
CTDSP1 Q9GZU7 1/20 0.54
RAB9A P51151 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2378698 0.88 PKM (0.75) PKMHPGDPHGDHKMT2AGLA
SCHEMBL16148988 0.83 HPGD (0.55) PKMHPGDKMT2APOLBL3MBTL1
SCHEMBL487574 0.83 PKM (0.77) PKMHPGDPHGDHKMT2AAKR1C3
SCHEMBL13161947 0.83 HPGD (1.00) PKMHPGDPHGDHKMT2AAKR1C3
SCHEMBL9996865 0.83 HSP90AA1 (0.63) PKMHPGDPHGDHKMT2AGLA
SCHEMBL2378109 0.82 HPGD (0.67) PKMHPGDPHGDHKMT2AGLA
SCHEMBL15652845 0.82 PKM (0.75) PKMHPGDPHGDHKMT2AAKR1C3
SCHEMBL332889 0.82 KMT2A (0.60) PKMHPGDPHGDHKMT2AGLA
SCHEMBL31533272 0.82 KMT2A (0.60) PKMHPGDPHGDHKMT2AGLA
SCHEMBL21201347 0.81 HSP90AA1 (0.56) PKMHPGDHSP90AA1HSP90AB1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050749-B1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-11-22 EP disclosed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 WO disclosed
US-8022205-B2 Pyrimidine derivatives as PI3K inhibitor and use thereof CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-09-20 US disclosed
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-18 US disclosed
EP-2050749-A1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO PKM 1188/4885HPGD 571/4885PHGDH 878/4885
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF PIK3CA, AKT3, AKT1 PKM 1376/4885HPGD 1383/4885PHGDH 900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.